Angiosarcoma Clinical Trial
Official title:
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
This study will be a multi-institutional, prospective, observational study of patients with localized primary AS of any site within ISG and RTR centers. Patients will be treated according to clinical practice of the center and according to ISG clinical recommendations on localized AS.
The management of localized AS remains a clinical challenge and needs to be better defined and standardized, especially with regards to the role of radiation-therapy and systemic treatment. Several questions about the best treatment approach to some clinical presentations remain open and would need to be answered by clinical studies. Unfortunately, the rarity of this histology among sarcomas makes it challenging to carry out clinical studies in all such presentations. Moreover, prognostic factors are lacking and differences in epidemiological, pathological and clinical aspects between primary AS and secondary AS need to be better characterized. These issues may be addressed with a prospective multi-institutional observational study, through the collection of clinical and pathological data of patients with localized AS. Involving all reference centres for sarcoma in Italy, the Italian Sarcoma Group (ISG) will be the ideal network for this study, with the collaboration of the Italian Rare Cancer Network (RTR), a 7collaborative network among Italian centres focusing on improving the quality of care of patients with rare tumors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Completed |
NCT01303497 -
Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
|
Phase 2 | |
| Recruiting |
NCT02625389 -
Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.
|
Phase 4 | |
| Completed |
NCT04293289 -
Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma
|
N/A | |
| Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT02732678 -
Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
| Recruiting |
NCT05799612 -
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
|
Phase 1 | |
| Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
| Recruiting |
NCT01042379 -
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01786889 -
Identification, Molecular Epidemiology Angiosarcoma of the Liver France
|
N/A | |
| Terminated |
NCT02212015 -
Evaluation of Votrient in Angiosarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03331250 -
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
|
Phase 2 | |
| Completed |
NCT02584309 -
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
| Not yet recruiting |
NCT06277154 -
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
|
Phase 2 | |
| Withdrawn |
NCT04607200 -
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
|
Phase 2 | |
| Completed |
NCT04518124 -
Propranolol in Angiosarcoma
|
Phase 2 | |
| Recruiting |
NCT05961761 -
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
|
Phase 2 | |
| Completed |
NCT00887809 -
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
|
Phase 2 |